MAIA Biotechnology (MAIA) director Stan V. Smith reports new stock purchases

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Stan V. Smith reported open-market purchases of the company’s common stock. On December 5, 2025, three separate transactions were reported, each for 4,580 shares of MAIA common stock at prices of $1.1997, $1.19, and $1.20 per share, all coded as purchases. These shares are held indirectly through three Illinois Uniform Transfers to Minors Act accounts for Mr. Smith’s family members, and he reports beneficial ownership only to the extent of his pecuniary interest.

In addition, the filing shows 1,364,289 shares of MAIA common stock beneficially owned indirectly through The Stan V. Smith Trust dated 1993. The form is filed as a single-reporting-person filing and reflects Mr. Smith’s status as a director of MAIA Biotechnology.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Stan

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/05/2025		P		4,580	A	$1.1997	4,580	I	See footnote(1)
Common Stock	12/05/2025		P		4,580	A	$1.19	4,580	I	See footnote(2)
Common Stock	12/05/2025		P		4,580	A	$1.2	4,580	I	See footnote(3)
Common Stock								1,364,289	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are beneficially owned by Mr. Smith through the Travis Deo Zai Zai Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

2. These securities are beneficially owned by Mr. Smith through the Gage Quentin Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

3. These securities are beneficially owned by Mr. Smith through the Blake Sarai Teitei Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

4. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

	/s/ Stan V. Smith	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

The filing reports that director Stan V. Smith made three open-market purchases of MAIA Biotechnology, Inc. common stock on December 5, 2025, each for 4,580 shares of common stock coded as purchases.

At what prices did Stan V. Smith buy MAIA Biotechnology (MAIA) shares?

Stan V. Smith reported purchasing 4,580 MAIA shares at $1.1997 per share, 4,580 shares at $1.19 per share, and 4,580 shares at $1.20 per share on December 5, 2025.

How many MAIA Biotechnology (MAIA) shares does Stan V. Smith report as beneficially owned?

After the reported transactions, the form shows 1,364,289 shares of MAIA common stock beneficially owned indirectly through The Stan V. Smith Trust dated 1993, plus three separate 4,580-share positions held through family UTMA accounts.

How are the newly purchased MAIA (MAIA) shares held by Stan V. Smith?

The newly purchased shares are indirectly held through three Illinois Uniform Transfers to Minors Act accounts for Mr. Smith’s family members. The responses note that he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.

What is Stan V. Smith’s relationship to MAIA Biotechnology (MAIA)?

Stan V. Smith is identified in the filing as a director of MAIA Biotechnology, Inc., and he is the sole reporting person on this Form 4.

Does this MAIA (MAIA) Form 4 involve any derivative securities?

No derivative securities are reported. Table II for derivative securities is present but contains no transactions or positions in the provided content.